Drug intelligence / Profile preview

vincristine + doxorubicin + actinomycin D + ifosfamide

Development stage: Unknown
Lead developer: King Faisal Specialist Hospital and Research Centre
Modality: Small Molecules
Administration: Intravenous

Overview

A multi-agent chemotherapy regimen evaluated by the King Faisal Specialist Hospital & Research Center for the treatment of Ewing sarcoma. This combination therapy includes vincristine, doxorubicin (Adriamycin), actinomycin D (dactinomycin), and ifosfamide. The regimen utilizes multiple mechanisms of action to combat tumor growth: vincristine is a vinca alkaloid that inhibits microtubule formation during mitosis; doxorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II; actinomycin D is a cytotoxic antibiotic that intercalates DNA and inhibits RNA synthesis; and ifosfamide acts as a DNA alkylating agent. This pilot study aimed to assess the efficacy and safety of this intensive combination in patients with the Ewing sarcoma family of tumors.

Other names: VAI regimenVACA regimenVincristine, Adriamycin, Actinomycin D, IfosfamideVincristine, Actinomycin-D, Ifosfamide

Targets

TOP2A (DNA topoisomerase II)Topoisomerase I/II-DNA cleavage complexesDNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on vincristine + doxorubicin + actinomycin D + ifosfamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vincristine + doxorubicin + actinomycin D + ifosfamide.

Explore the full profile